Verapamil as Therapy for Children and Young Adults With Dravet Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Dravet Syndrome
Interventions
DRUG

Verapamil

"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."

Trial Locations (4)

55101

Gillette Children's Specialty Healthcare, Saint Paul

55905

Mayo Clinic, Rochester

60614

Children's Memorial Hospital, Chicago

03756

Mary Hitchcock Memorial Hospital, Lebanon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

collaborator

Dartmouth-Hitchcock Medical Center

OTHER

lead

Gillette Children's Specialty Healthcare

OTHER